While CAR-T-cell therapy for the BCMA has been a prominent focus, BCMA bispecific antibodies have emerged as a promising alternative for addressing relapsed and refractory MM (RRMM). This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.